Atlas Trials

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Clinical trial NCT06564324 · RECRUITING

Trial details

NCT number
NCT06564324
Sponsor
Nuvation Bio Inc.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2024-11-27
Primary completion
2029-01-01
Enrollment
194

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.